Literature DB >> 12915557

Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?

Tulio de Oliveira1, Susan Engelbrecht, Estrelita Janse van Rensburg, Michelle Gordon, Karen Bishop, Jan zur Megede, Susan W Barnett, Sharon Cassol.   

Abstract

Naturally occurring polymorphisms in the protease of human immunodeficiency virus type 1 (HIV-1) subtype C would be expected to lead to adaptive (compensatory) changes in protease cleavage sites. To test this hypothesis, we examined the prevalences and patterns of cleavage site polymorphisms in the Gag, Gag-Pol, and Nef cleavage sites of C compared to those in non-C subtypes. Codon-based maximum-likelihood methods were used to assess the natural selection and evolutionary history of individual cleavage sites. Seven cleavage sites (p17/p24, p24/p2, NC/p1, NC/TFP, PR/RT, RT/p66, and p66/IN) were well conserved over time and in all HIV-1 subtypes. One site (p1/p6(gag)) exhibited moderate variation, and four sites (p2/NC, TFP/p6(pol), p6(pol)/PR, and Nef) were highly variable, both within and between subtypes. Three of the variable sites are known to be major determinants of polyprotein processing and virion production. P2/NC controls the rate and order of cleavage, p6(gag) is an important phosphoprotein required for virion release, and TFP/p6(pol), a novel cleavage site in the transframe domain, influences the specificity of Gag-Pol processing and the activation of protease. Overall, 58.3% of the 12 HIV-1 cleavage sites were significantly more diverse in C than in B viruses. When analyzed as a single concatenated fragment of 360 bp, 96.0% of group M cleavage site sequences fell into subtype-specific phylogenetic clusters, suggesting that they coevolved with the virus. Natural variation at C cleavage sites may play an important role, not only in regulation of the viral cycle but also in disease progression and response to therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915557      PMCID: PMC187406          DOI: 10.1128/jvi.77.17.9422-9430.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Novel evolutionary analyses of full-length HIV type 1 subtype C molecular clones from Cape Town, South Africa.

Authors:  Jan zur Megede; Susan Engelbrecht; Tulio de Oliveira; Sharon Cassol; Thomas J Scriba; Estrelita Janse van Rensburg; Susan W Barnett
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-20       Impact factor: 2.205

2.  Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies.

Authors:  M Gordon; T De Oliveira; K Bishop; H M Coovadia; L Madurai; S Engelbrecht; E Janse van Rensburg; A Mosam; A Smith; S Cassol
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease.

Authors:  S Billich; M T Knoop; J Hansen; P Strop; J Sedlacek; R Mertz; K Moelling
Journal:  J Biol Chem       Date:  1988-12-05       Impact factor: 5.157

4.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

Authors:  T Jacks; M D Power; F R Masiarz; P A Luciw; P J Barr; H E Varmus
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

5.  Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.

Authors:  S Erickson-Viitanen; J Manfredi; P Viitanen; D E Tribe; R Tritch; C A Hutchison; D D Loeb; R Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  1989-12       Impact factor: 2.205

6.  The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.

Authors:  A H Kaplan; M Manchester; R Swanstrom
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

7.  Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates.

Authors:  J Tözsér; P Bagossi; P Boross; J M Louis; E Majerova; S Oroszlan; T D Copeland
Journal:  Eur J Biochem       Date:  1999-10-01

8.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides.

Authors:  H G Kräusslich; R H Ingraham; M T Skoog; E Wimmer; P V Pallai; C A Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

10.  Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

Authors:  Sarah C Ball; Awet Abraha; Kalonji R Collins; Andre J Marozsan; Heather Baird; Miguel E Quiñones-Mateu; Adam Penn-Nicholson; Michael Murray; Nathalie Richard; Michael Lobritz; Peter A Zimmerman; Tatsuyoshi Kawamura; Andrew Blauvelt; Eric J Arts
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  28 in total

1.  Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease.

Authors:  Oscar Alvizo; Seema Mittal; Stephen L Mayo; Celia A Schiffer
Journal:  Protein Sci       Date:  2012-06-05       Impact factor: 6.725

2.  Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a linker cleavable by specific proteases.

Authors:  Jung-Ho Park; Yoshihiro Yamaguchi; Masayori Inouye
Journal:  Appl Environ Microbiol       Date:  2012-03-23       Impact factor: 4.792

3.  The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.

Authors:  Rajintha M Bandaranayake; Madhavi Kolli; Nancy M King; Ellen A Nalivaika; Annie Heroux; Junko Kakizawa; Wataru Sugiura; Celia A Schiffer
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

4.  A substrate selected by phage display exhibits enhanced side-chain hydrogen bonding to HIV-1 protease.

Authors:  Ian W Windsor; Ronald T Raines
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-06-27       Impact factor: 7.652

5.  Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness.

Authors:  Terrence W Brann; Robin L Dewar; Min-Kan Jiang; Akram Shah; Kunio Nagashima; Julia A Metcalf; Judith Falloon; H Clifford Lane; Tomozumi Imamichi
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery.

Authors:  Mahdieh Soezi; Arash Memarnejadian; Saeed Aminzadeh; Rezvan Zabihollahi; Seyed Mehdi Sadat; Safieh Amini; Soheila Hekmat; Mohammad Reza Aghasadeghi
Journal:  Rep Biochem Mol Biol       Date:  2015-10

7.  Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.

Authors:  Jennifer Giandhari; Adriaan E Basson; Ashraf Coovadia; Louise Kuhn; Elaine J Abrams; Renate Strehlau; Lynn Morris; Gillian M Hunt
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-04       Impact factor: 2.205

8.  Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.

Authors:  Sergey Iordanskiy; Mackenzie Waltke; Yanjun Feng; Charles Wood
Journal:  Retrovirology       Date:  2010-10-12       Impact factor: 4.602

9.  Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design?

Authors:  Tulio de Oliveira; Marco Salemi; Michelle Gordon; Anne-Mieke Vandamme; Estrelita Janse van Rensburg; Susan Engelbrecht; Hoosen M Coovadia; Sharon Cassol
Journal:  Genetics       Date:  2004-07       Impact factor: 4.562

10.  Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production.

Authors:  Emiko Urano; Toru Aoki; Yuko Futahashi; Tsutomu Murakami; Yuko Morikawa; Naoki Yamamoto; Jun Komano
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.